Shares of Viking Therapeutics (VKTX) are up $2.34, or 58%, to $6.36 after competitor Madrigal Pharmaceuticals (MDGL) announced topline results from the pivotal Phase 3 MAESTRO-NASH biopsy clinical trial of resmetirom, a liver-directed selective thyroid hormone receptor agonist. MAESTRO-NASH, a registrational Phase 3 trial, achieved both liver histological improvement endpoints that FDA proposed as reasonably likely to predict clinical benefit to support accelerated approval for the treatment NASH with liver fibrosis, Madrigal reported earlier this morning. In morning trading, shares of Madrigal Pharmaceuticals are up $168.03, or 263%, to $231.83.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly